Geode Capital Management
BCAX

Geode Capital Management’s Bicara Therapeutics BCAX Stock Holding History

Geode Capital Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.5M Buy
1,162,635
+331,729
+40% +$7.4M ﹤0.01% 1833
2026
Q1 		$16.5M Buy
830,906
+19,506
+2% +$336K ﹤0.01% 2098
2025
Q4 		$13.7M Sell
811,400
-19,808
-2% -$338K ﹤0.01% 2231
2025
Q3 		$13.1M Buy
831,208
+158,723
+24% +$1.78M ﹤0.01% 2252
2025
Q2 		$6.25M Buy
672,485
+180,833
+37% +$2.16M ﹤0.01% 2617
2025
Q1 		$6.41M Buy
491,652
+25,010
+5% +$332K ﹤0.01% 2535
2024
Q4 		$8.13M Buy
466,642
+418,003
+859% +$8.7M ﹤0.01% 2488
2024
Q3 		$1.24M Buy
+48,639
New +$1.24M ﹤0.01% 3283

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management's BCAX Position: Q2 2026 in Review

Geode Capital Management increased its Bicara Therapeutics (BCAX) stake by 40% in Q2 2026, buying an estimated $7.4M and bringing the position to 1,162,635 shares worth $34.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1833.

Geode Capital Management first reported a position in BCAX in Q3 2024 and has held it in 8 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Geode Capital Management held 1,162,635 shares of Bicara Therapeutics worth $34.5M as of Q2 2026.
  • Geode Capital Management bought 331,729 Bicara Therapeutics shares in Q2 2026, an estimated $7.4M.
  • Bicara Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #1833 holding.
  • Geode Capital Management first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.